Literature DB >> 10454725

Elongation of (CTG)n repeats in myotonic dystrophy protein kinase gene in tumors associated with myotonic dystrophy patients.

K Jinnai1, T Sugio, M Mitani, K Hashimoto, K Takahashi.   

Abstract

Length of (CTG)n triplet repeats in myotonic dystrophy protein kinase gene (DMPK) was estimated in tumors, normal tissues of the same organs, muscles, and leukocytes from three myotonic dystrophy (DM) patients and a non-DM patient. Using cDNA 25 as a probe, a Southern blot analysis of EcoRI- and BglI-digested DNA from these tissues demonstrated the longest expansion of the repeats in the tumors of DM patients. In all tissues from a non-DM patient, the repeat length was confirmed to be stable by PCR analysis. Our data suggest that expanded (CTG)n repeat in tumor tissues may have increased the instability. This study emphasizes the importance of a long-term prospective study on the incidence of tumors in DM to clarify the pathological interrelation between the two entities. Copyright 1999 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454725     DOI: 10.1002/(sici)1097-4598(199909)22:9<1271::aid-mus16>3.0.co;2-d

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

1.  Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1.

Authors:  Jessica Feng; Avery LaChance; David A Sinclair; Maryam M Asgari
Journal:  BMJ Case Rep       Date:  2019-03-08

2.  Correlates of tumor development in patients with myotonic dystrophy.

Authors:  Maya Das; Richard T Moxley; James E Hilbert; William B Martens; Lisa Letren; Mark H Greene; Shahinaz M Gadalla
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

3.  A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy.

Authors:  Diana Abbott; Nicholas E Johnson; Lisa A Cannon-Albright
Journal:  Muscle Nerve       Date:  2016-07-07       Impact factor: 3.217

Review 4.  Hypothesis: neoplasms in myotonic dystrophy.

Authors:  Christine M Mueller; James E Hilbert; William Martens; Charles A Thornton; Richard T Moxley; Mark H Greene
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

5.  Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity.

Authors:  Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla
Journal:  JNCI Cancer Spectr       Date:  2018-12-10

6.  Neuropathology does not Correlate with Regional Differences in the Extent of Expansion of CTG Repeats in the Brain with Myotonic Dystrophy Type 1.

Authors:  Kyoko Itoh; Maki Mitani; Kunihiko Kawamoto; Naonobu Futamura; Itaru Funakawa; Kenji Jinnai; Shinji Fushiki
Journal:  Acta Histochem Cytochem       Date:  2010-12-18       Impact factor: 1.938

7.  A giant uterine tumor in a woman with myotonic dystrophy.

Authors:  Hiroshi Kataoka; Satoshi Ueno
Journal:  Clin Case Rep       Date:  2017-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.